Home > News > Nanogen and Epoch Biosciences Agree to Merge
September 7th, 2004
Nanogen and Epoch Biosciences Agree to Merge
Abstract:
Nanogen, Inc. (Nasdaq: NGEN), a developer of advanced in vitro diagnostic products, and Epoch Biosciences, Inc. (Nasdaq: EBIO), a provider of proprietary products that accelerate genomic analysis, announced today the signing of a definitive agreement to merge Epoch into Nanogen in an all-stock transaction. Epoch has a variety of products that are complementary to Nanogen's, and the merger will expand Nanogen's reach in the rapidly growing clinical lab and research markets.
Source:
corporate-ir
Bookmark:
| Related News Press |
Investments/IPO's/Splits
Daikin Industries becomes OCSiAl shareholder July 27th, 2021
INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Announcements
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Quantum computers simulate fundamental physics: shedding light on the building blocks of nature June 6th, 2025
A 1960s idea inspires NBI researchers to study hitherto inaccessible quantum states June 6th, 2025
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||